Cargando…

Arthritis and Myositis in a Patient Treated with Programmed Cell Death-1 (PD-1) Inhibitor Pembrolizumab for Lung Cancer

Immune checkpoint inhibitors (ICIs) are a new class of drug that have demonstrated efficacy across many cancer types. Because of their nature and mode of action, ICIs unleash immune activation raising concerns as to whether they can be used in patients with concomitant autoimmune or auto-inflammator...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pagkopoulou, Eleni, Simopoulou, Theodora, Maragkouli, Eleni, Perifanou-Sotiri, Stamatia, Kotsakis, Athanasios, Bogdanos, Dimitrios P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Mediterranean Journal of Rheumatology (MJR) 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641028/ https://www.ncbi.nlm.nih.gov/pubmed/33163870 http://dx.doi.org/10.31138/mjr.31.3.355

Ejemplares similares

Pembrolizumab-Induced Myasthenia Gravis and Myositis: Literature Review on Neurological Toxicities of Programmed Death Protein 1 Inhibitors
por: Schwab, Alfred, et al.
Publicado: (2022)

COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report
por: Syrmou, Vasiliki, et al.
Publicado: (2023)

CD8(+) PD-1(+) T-cells and PD-L1(+) circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?
por: Kotsakis, Athanasios, et al.
Publicado: (2019)

JAK Inhibition in Patients with Rheumatoid Arthritis: Haemodynamic Effects and Impact on Micro- and Macrovascular Function. Study Design and Rationale
por: Anyfanti, Panagiota, et al.
Publicado: (2022)

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
por: Kallergi, Galatea, et al.
Publicado: (2018)

Paraspinal muscle involvement in pembrolizumab-associated myositis
por: Nosaki, Yasunobu, et al.
Publicado: (2020)

Curcumin for the Management of Periodontitis and Early ACPA-Positive Rheumatoid Arthritis: Killing Two Birds with One Stone
por: Asteriou, Eleni, et al.
Publicado: (2018)

Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors
por: Ferrucci, Pier Francesco
Publicado: (2023)

Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment
por: Zarogoulidis, Paul, et al.
Publicado: (2017)

Study of Peripheral Microcirculation Assessed by Nailfold Video-Capillaroscopy and Association with Markers of Endothelial Dysfunction and Inflammation in Rheumatoid Arthritis
por: Angeloudi, Elena, et al.
Publicado: (2022)

Nutritional Aspects of Juvenile Idiopathic Arthritis: An A to Z for Dietitians
por: Grammatikopoulou, Maria G., et al.
Publicado: (2023)

The Effect of Pembrolizumab in Absence of Programmed Death 1 Receptor
por: Al Attar, Layth, et al.
Publicado: (2018)

Saddle Nose with Recurrent Sinusitis and Arthralgias: a Not-to-lose Diagnosis
por: Syrmou, Vassiliki, et al.
Publicado: (2022)

Giant Hip Synovial Cyst Causing Deep Vein Thrombosis and Femoral Head Osteonecrosis in a Rheumatoid Arthritis Patient
por: Syrmou, Vasiliki, et al.
Publicado: (2022)

Pembrolizumab‐induced myasthenia gravis with myositis in a patient with lung cancer
por: Hibino, Makoto, et al.
Publicado: (2018)

Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm
por: Haddox, C. L., et al.
Publicado: (2017)

Pembrolizumab on pre-existing inclusion body myositis: a case report
por: Uchio, Naohiro, et al.
Publicado: (2020)

Granulomatous myositis induced by anti–PD-1 monoclonal antibodies
por: Uchio, Naohiro, et al.
Publicado: (2018)

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2022)

The Three P's: Parotid, PD-L1, and Pembrolizumab
por: Wiggins, Amanda, et al.
Publicado: (2019)

Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1
por: Wang, Simiao, et al.
Publicado: (2023)

Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer
por: Huh, So-Young, et al.
Publicado: (2018)

PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2021)

Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer
por: Vetsika, Eleni-Kyriaki, et al.
Publicado: (2019)

Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
por: Todo, Maki, et al.
Publicado: (2019)

Early development of pembrolizumab‐induced fulminant myositis and cardiotoxicity in a patient with metastatic thymoma
por: Jang, Soo Yeon, et al.
Publicado: (2022)

Flow Cytometric Detection of p38 MAPK Phosphorylation and Intracellular Cytokine Expression in Peripheral Blood Subpopulations from Patients with Autoimmune Rheumatic Diseases
por: Mavropoulos, Athanasios, et al.
Publicado: (2014)

The Role of Flavonoids in Inhibiting Th17 Responses in Inflammatory Arthritis
por: Kelepouri, Dimitra, et al.
Publicado: (2018)

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
por: Incorvaia, Lorena, et al.
Publicado: (2019)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Pembrolizumab Induces an Unexpected Conformational Change in the CC′-loop of PD-1
por: Roither, Bernhard, et al.
Publicado: (2020)

PD46 - Serum level of S 100 proteins in patients with asthma
por: Gioka, Theodora, et al.
Publicado: (2014)

Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report
por: Tian, Chia-Yi, et al.
Publicado: (2021)

Editorial Comment to Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
por: Tomisaki, Ikko
Publicado: (2019)

Primary MRSA Myositis Mimicking Septic Arthritis
por: Abu-Abaa, Mohammad, et al.
Publicado: (2023)

Inflammatory cytokines compromise programmed cell death‐1 (PD‐1)‐mediated T cell suppression in inflammatory arthritis through up‐regulation of soluble PD‐1
por: Bommarito, D., et al.
Publicado: (2017)

Clinical and histopathological features of myositis in systemic lupus erythematosus
por: Tiniakou, Eleni, et al.
Publicado: (2022)

Cardiovascular complications after COVID-19 in chronic kidney disease, dialysis and kidney transplant patients
por: Loutradis, Charalampos, et al.
Publicado: (2021)

The Role of p38 MAPK in the Aetiopathogenesis of Psoriasis and Psoriatic Arthritis
por: Mavropoulos, Athanasios, et al.
Publicado: (2013)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dtasf5os1vei62mt88p7mbargr